- SKYCellflu ® Quadrivalent is now available to vaccinate everyone 6 months or older

- The vaccine is expected to play a leading role in this fall and winter influenza season

SK bioscience announced on the 23rd that the company has received an approval from the Ministry of Food and Drug Safety(KMFDS) for the quadrivalent cell culture influenza vaccine, SKYCellflu Quadrivalent, to be administered to infants between 6 months to 3 years of age, allowing SKYCellflu Quadrivalent to be administered to all age groups 6 months or older.

Last December, SKYCellflu Quadrivalent became the first quadrivalent cell culture-based influenza vaccine to acquire the WHO Prequalification certification. The vaccine is expected to gain momentum in the domestic market and expand sales overseas.

Jaeyong Ahn, CEO of SK bioscience said, “With the expanded approval of our influenza vaccine to infant vaccination, we can now provide the cell culture-based influenza vaccine to all age groups, With proven efficacy and safety, the vaccine is expected to play a leading role in this year´s influenza vaccine market.”